Phase 2 data showed mean weight loss of up to 24.2% at 48 weeks, which, if confirmed in phase 3 trials, would surpass both CagriSema and tirzepatide
Weight loss often occurs, but it is considered a secondary benefit , not the primary treatment goal
Practical guidance: For doses below 1.0 mg, use a 0.3 mL or 0.5 mL barrel syringe with half-unit markings
Patients should also report any symptoms of pancreatitis (severe abdominal pain, sometimes radiating to the back, with or without vomiting), gallbladder problems, or changes in vision, as these may require prompt medical attention and reassessment of treatment
It is brought on, in most cases, by changes in hormones that are flowing through the body and in cell growth
PlexusDx serves patients seeking personalized weight loss solutions at life transitions